First Time Loading...

Pulmonx Corp
NASDAQ:LUNG

Watchlist Manager
Pulmonx Corp Logo
Pulmonx Corp
NASDAQ:LUNG
Watchlist
Price: 7.3 USD -2.93% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

LUNG's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. [ Read More ]

The intrinsic value of one LUNG stock under the Base Case scenario is 10.84 USD. Compared to the current market price of 7.3 USD, Pulmonx Corp is Undervalued by 33%.

Key Points:
LUNG Intrinsic Value
Base Case
10.84 USD
Undervaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pulmonx Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LUNG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Pulmonx Corp

Provide an overview of the primary business activities
of Pulmonx Corp.

What unique competitive advantages
does Pulmonx Corp hold over its rivals?

What risks and challenges
does Pulmonx Corp face in the near future?

Has there been any significant insider trading activity
in Pulmonx Corp recently?

Summarize the latest earnings call
of Pulmonx Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pulmonx Corp.

Provide P/S
for Pulmonx Corp.

Provide P/E
for Pulmonx Corp.

Provide P/OCF
for Pulmonx Corp.

Provide P/FCFE
for Pulmonx Corp.

Provide P/B
for Pulmonx Corp.

Provide EV/S
for Pulmonx Corp.

Provide EV/GP
for Pulmonx Corp.

Provide EV/EBITDA
for Pulmonx Corp.

Provide EV/EBIT
for Pulmonx Corp.

Provide EV/OCF
for Pulmonx Corp.

Provide EV/FCFF
for Pulmonx Corp.

Provide EV/IC
for Pulmonx Corp.

Show me price targets
for Pulmonx Corp made by professional analysts.

What are the Revenue projections
for Pulmonx Corp?

How accurate were the past Revenue estimates
for Pulmonx Corp?

What are the Net Income projections
for Pulmonx Corp?

How accurate were the past Net Income estimates
for Pulmonx Corp?

What are the EPS projections
for Pulmonx Corp?

How accurate were the past EPS estimates
for Pulmonx Corp?

What are the EBIT projections
for Pulmonx Corp?

How accurate were the past EBIT estimates
for Pulmonx Corp?

Compare the revenue forecasts
for Pulmonx Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pulmonx Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pulmonx Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pulmonx Corp compared to its peers.

Compare the P/E ratios
of Pulmonx Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Pulmonx Corp with its peers.

Analyze the financial leverage
of Pulmonx Corp compared to its main competitors.

Show all profitability ratios
for Pulmonx Corp.

Provide ROE
for Pulmonx Corp.

Provide ROA
for Pulmonx Corp.

Provide ROIC
for Pulmonx Corp.

Provide ROCE
for Pulmonx Corp.

Provide Gross Margin
for Pulmonx Corp.

Provide Operating Margin
for Pulmonx Corp.

Provide Net Margin
for Pulmonx Corp.

Provide FCF Margin
for Pulmonx Corp.

Show all solvency ratios
for Pulmonx Corp.

Provide D/E Ratio
for Pulmonx Corp.

Provide D/A Ratio
for Pulmonx Corp.

Provide Interest Coverage Ratio
for Pulmonx Corp.

Provide Altman Z-Score Ratio
for Pulmonx Corp.

Provide Quick Ratio
for Pulmonx Corp.

Provide Current Ratio
for Pulmonx Corp.

Provide Cash Ratio
for Pulmonx Corp.

What is the historical Revenue growth
over the last 5 years for Pulmonx Corp?

What is the historical Net Income growth
over the last 5 years for Pulmonx Corp?

What is the current Free Cash Flow
of Pulmonx Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pulmonx Corp.

Financials

Balance Sheet Decomposition
Pulmonx Corp

Current Assets 150.4m
Cash & Short-Term Investments 58.7m
Receivables 13m
Other Current Assets 78.7m
Non-Current Assets 27.4m
Long-Term Investments 14.4m
PP&E 7.4m
Intangibles 2.4m
Other Non-Current Assets 3.2m
Current Liabilities 23.2m
Accounts Payable 1.5m
Accrued Liabilities 18.8m
Other Current Liabilities 2.8m
Non-Current Liabilities 36.3m
Long-Term Debt 35.1m
Other Non-Current Liabilities 1.2m
Efficiency

Earnings Waterfall
Pulmonx Corp

Revenue
68.7m USD
Cost of Revenue
-17.9m USD
Gross Profit
50.8m USD
Operating Expenses
-112.7m USD
Operating Income
-61.9m USD
Other Expenses
1.1m USD
Net Income
-60.8m USD

Free Cash Flow Analysis
Pulmonx Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

LUNG Profitability Score
Profitability Due Diligence

Pulmonx Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Exceptional Revenue Growth Forecast
28/100
Profitability
Score

Pulmonx Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

LUNG Solvency Score
Solvency Due Diligence

Pulmonx Corp's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
52/100
Solvency
Score

Pulmonx Corp's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LUNG Price Targets Summary
Pulmonx Corp

Wall Street analysts forecast LUNG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LUNG is 16.52 USD with a low forecast of 14.14 USD and a high forecast of 17.85 USD.

Lowest
Price Target
14.14 USD
94% Upside
Average
Price Target
16.52 USD
126% Upside
Highest
Price Target
17.85 USD
145% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LUNG Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LUNG Price
Pulmonx Corp

1M 1M
-19%
6M 6M
-10%
1Y 1Y
-38%
3Y 3Y
-85%
5Y 5Y
-81%
10Y 10Y
-81%
Annual Price Range
7.3
52w Low
7.3
52w High
14.65
Price Metrics
Average Annual Return -22.54%
Standard Deviation of Annual Returns 67.17%
Max Drawdown -93%
Shares Statistics
Market Capitalization 281.2m USD
Shares Outstanding 38 811 800
Percentage of Shares Shorted 4.14%

LUNG Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Pulmonx Corp Logo
Pulmonx Corp

Country

United States of America

Industry

Health Care

Market Cap

281.2m USD

Dividend Yield

0%

Description

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Contact

CALIFORNIA
Redwood City
700 Chesapeake Dr
+16503640400.0
https://pulmonx.com/

IPO

2020-10-01

Employees

253

Officers

General Counsel & Secretary
Mr. David A. Lehman
Chief Commercial Officer
Mr. Geoffrey Beran Rose
CEO, President & Director
Mr. Steven S. Williamson
Interim CFO
Mr. John B. McKune
Chief Technical Officer
Mr. Sri Radhakrishnan
Vice President of Marketing
Ms. Marcee M. Maroney
Show More
Vice President of Sales (U.S.)
Sarah Huber
Chief People Officer
Ms. Lisa Paul
Senior VP & GM of Europe Middle-East & Africa
Mr. Jérôme Erath
Show Less

See Also

Discover More
What is the Intrinsic Value of one LUNG stock?

The intrinsic value of one LUNG stock under the Base Case scenario is 10.84 USD.

Is LUNG stock undervalued or overvalued?

Compared to the current market price of 7.3 USD, Pulmonx Corp is Undervalued by 33%.